

Saving Hearts and Lives in Advanced Prostate Cancer: Choosing Between ADT Agonists and Antagonists – Tweetorial #3

References

Tweet 4

SEER. Cancer stat facts: prostate cancer. National Cancer Institute. Accessed August 12, 2021. <https://seer.cancer.gov/statfacts/html/prost.html>

SEER*Explorer. An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed August 12, 2021. <https://seer.cancer.gov/explorer/>

Tweet 5

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer (v2.2022). Updated November 30, 2021. Accessed December 21, 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Tweet 6

Cohen Castel O, Dagan E, Keinan-Boker L, Low M, Shadmi E. Patients' perceived continuity of care and adherence to oral anticancer therapy: a prospective cohort mediation study. *J Gen Intern Med.* 2021;36(6):1525-1532. doi:10.1007/s11606-021-06704-w

FIRMAGON® (degarelix). Prescribing information. Ferring; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022201s016lbl.pdf

LUPRON DEPOT® (leuprolide). Prescribing information. AbbVie Inc.; 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020517s042_019732s044lbl.pdf

ORGOVYX® (relugolix). Prescribing information. Myovant Sciences, Inc.; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf

TRELSTAR® (triptorelin). Prescribing information. Allergan; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020715s040_021288s035_022427s015lbl.pdf

ZOLADEX® (goserelin) 3.6 mg. Prescribing information. AstraZeneca; 2020. https://documents.tercera.com/zoladex-us/3.6mg_MagnumPI.pdf

ZOLADEX® (goserelin) 10.8 mg. Prescribing information. AstraZeneca; 2020. https://documents.tercera.com/zoladex-us/10.8mg_MagnumPI.pdf

Tweet 8

Bolton EM, Lynch T. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. *BJU Int.* 2018;122(3):371-383. doi:10.1111/bju.14168

Borrelli E, McGladrigan CG. PCN80 estimating the difference in annual out-of-pocket costs for relugolix and leuprolide for medicare patients with metastatic prostate cancer. *Value in Health*. 2021;24:S34. doi:10.1016/j.jval.2021.04.172

Cohen Castel O, Dagan E, Keinan-Boker L, Low M, Shadmi E. Patients' perceived continuity of care and adherence to oral anticancer therapy: a prospective cohort mediation study. *J Gen Intern Med*. 2021;36(6):1525-1532. doi:10.1007/s11606-021-06704-w

Dowling M, Hunter A, Biesty L, et al. Driving and disabling factors of noncurative oral chemotherapy adherence: a qualitative evidence synthesis. *Oncol Nurs Forum*. 2019;46(1):16-28. doi:10.1188/19.ONF.16-28

Tweet 9

Dean LT, George M, Lee KT, Ashing K. Why individual-level interventions are not enough: Systems-level determinants of oral anticancer medication adherence. *Cancer*. 2020;126(16):3606-3612. doi:10.1002/cncr.32946

Sabaté E. *Adherence to Long-term Therapies: Evidence for Action*. World Health Organization; 2003. Accessed October 1, 2021. <https://apps.who.int/iris/handle/10665/42682>

Tweet 10

Dowling M, Hunter A, Biesty L, et al. Driving and disabling factors of noncurative oral chemotherapy adherence: a qualitative evidence synthesis. *Oncol Nurs Forum*. 2019;46(1):16-28. doi:10.1188/19.ONF.16-28

Tweet 12

Cohen Castel O, Dagan E, Keinan-Boker L, Low M, Shadmi E. Patients' perceived continuity of care and adherence to oral anticancer therapy: a prospective cohort mediation study. *J Gen Intern Med*. 2021;36(6):1525-1532. doi:10.1007/s11606-021-06704-w

Dowling M, Hunter A, Biesty L, et al. Driving and disabling factors of noncurative oral chemotherapy adherence: a qualitative evidence synthesis. *Oncol Nurs Forum*. 2019;46(1):16-28. doi:10.1188/19.ONF.16-28

Sabaté E. *Adherence to Long-term Therapies: Evidence for Action*. World Health Organization; 2003. Accessed October 1, 2021. <https://apps.who.int/iris/handle/10665/42682>

Tweet 13

Kaptein AA, Schoones JW, van der Meer PB, et al. Psychosocial determinants of adherence with oral anticancer treatment: 'we don't need no education'. *Acta Oncol*. 2021;60(1):87-95. doi:10.1080/0284186X.2020.1843190

Sabaté E. *Adherence to Long-term Therapies: Evidence for Action*. World Health Organization; 2003. Accessed October 1, 2021. <https://apps.who.int/iris/handle/10665/42682>

Tweet 14

Weinman J, Ali I, Hodgkinson A, Canfield M, Jackson C. Pilot testing of a brief pre-consultation screener for improving the identification and discussion of medication adherence in routine consultations. *Patient Prefer Adherence*. 2019;13:1895-1898. doi:10.2147/PPA.S219860

Tweet 15

Cohen Castel O, Dagan E, Keinan-Boker L, Low M, Shadmi E. Patients' perceived continuity of care and adherence to oral anticancer therapy: a prospective cohort mediation study. *J Gen Intern Med*. 2021;36(6):1525-1532. doi:10.1007/s11606-021-06704-w

Tweet 16

Dowling M, Hunter A, Biesty L, et al. Driving and disabling factors of noncurative oral chemotherapy adherence: a qualitative evidence synthesis. *Oncol Nurs Forum*. 2019;46(1):16-28. doi:10.1188/19.ONF.16-28

Sabaté E. *Adherence to Long-term Therapies: Evidence for Action*. World Health Organization; 2003. Accessed October 1, 2021. <https://apps.who.int/iris/handle/10665/42682>

Glossary

ADT, androgen deprivation therapy
AEs, adverse events
BMQ, Beliefs about Medicines Questionnaire
COC, continuity of care
Coef, beta coefficient
CV, cardiovascular
EMR, electronic medical record
EBRT, external beam radiation therapy
GnRH, gonadotropin releasing hormone
HCP, healthcare professional
MO, nonmetastatic
MMAS4, Morisky Medication Adherence Scale
MMWFU, Making Medicines Work For You
NCCN, National Comprehensive Cancer Network
PCa, prostate cancer
PCP, primary care provider
PSA, prostate specific antigen
QOL, quality of life
RP, radical prostatectomy
RT, radiation therapy
SEER, Surveillance, Epidemiology, and End Results program
SOC, standard of care
w/, with